IDEXX Laboratories, Inc.

IDXX · NASDAQ · USD

Can IDEXX keep growing diagnostics revenue near double digits through testing intensity and new products while U.S. clinic visits keep declining?

Last 4 earnings calls · through Q2 FY2026

Bull case

  • Testing per visit expands

    Diagnostics demand is growing faster than clinic visits, so revenue comes from how much testing each visit includes rather than from more visits.

  • Instrument menu additions

    Each new analyzer and menu addition raises the recurring revenue an installed instrument generates, and management keeps lifting its placement plans.

  • Cancer panel expansion

    Cancer testing is shifting from a single test to a multi-cancer panel that brings in clinics loyal to competing reference laboratories.

  • Recurring revenue margin

    Recurring consumable and laboratory revenue is growing faster than costs, so margins and cash conversion both improve as volume rises.

Bear case

  • Falling clinic visits

    U.S. clinic visits keep falling, and the plan assumes the decline continues rather than reverses, so growth must come from within the visit.

  • Instrument sales rollover

    Instrument placements are rolling over after a record launch year, turning capital sales from the fastest growth line into a year-over-year drag.

  • Pricing and buyer consolidation

    Growth leans more on volume as price increases moderate, while consolidated corporate practice groups use their scale to bargain on price.

  • One-off earnings benefits

    Reported profit includes tax benefits from share-based compensation and currency gains that are unlikely to repeat at the same size each year.

Bull and bear points

Growth & Execution

In short: Recurring diagnostic revenue grows double digits on new products, but U.S. clinic visits keep declining.

Bull · 3

  • U.S. clinic visit outlook improved after three quarters of gains in older pets

    Management guided 2026 U.S. clinic visits down about 2% and now plans for a 1.5% decline, citing three quarters of growth in pets five and older.

    Tone shiftQ4 FY2025 → Q1 FY2026

  • InVue recurring revenue per analyzer is inside the target range

    Management says consumable revenue per InVue Dx analyzer is tracking inside its $3,500 to $5,500 range, and broader FNA availability is expected to add more.

    Q2 FY2026 call

  • Cancer Dx becomes a multi-cancer panel in late Q3

    Cancer Dx expands from a lymphoma test to a panel covering about a third of common canine cancers at no added price, which supports wellness bloodwork inclusion.

    Q2 FY2026 call
Bear · 2

  • Instrument revenue turns from growth driver to drag

    A year ago management raised InVue placements to about 6,000 units and over $65 million of instrument revenue; now instrument revenue falls 20% as that launch is lapped.

    Tone shiftQ3 FY2025 → Q2 FY2026

  • Growth plan assumes clinic visits keep declining

    The 2026 plan assumes U.S. clinic visits keep falling, and the low end of the recurring revenue range assumes no improvement in the sector.

    Q4 FY2025 call

Profitability & Financial Strength

In short: Gross margin and cash conversion are rising, but instrument mix and one-off tax benefits temper earnings.

Bull · 1

  • Gross margin expands on recurring revenue mix

    Gross margin reached 64% in the second quarter, up 1.4 points, as consumable and reference lab volume grew faster than costs and product costs stayed favorable.

    Filed financials
Bear · 2

  • Instrument sales dilute gross margin while they grow

    Capital equipment carries lower margins than consumables, so quarters with heavy instrument revenue curb the gross margin gain that recurring revenue otherwise delivers.

    Q4 FY2025 call

  • Reported EPS includes recurring tax and currency help

    Second quarter EPS included a 14-cent tax benefit from share-based compensation and six cents from currency, so reported growth outruns the underlying business.

    Q2 FY2026 call

Market Position

In short: High retention and cancer-test switching support share gains, but corporate customers press on pricing.

Bull · 2

  • Cancer Dx pulls orders from competing reference labs

    More than 20% of Cancer Dx orders come from practices using a competing lab, and management reports record lab conversions as those clinics move volume to IDEXX.

    Q2 FY2026 call

  • Retention in the high 90s protects recurring revenue

    Retention in IDEXX's companion animal diagnostics business stays in the high 90s, which keeps the consumable and reference lab revenue base from eroding.

    Q2 FY2026 call
Bear · 3

  • Global net price realization steps down in 2026

    Price added 4% to 4.5% globally in 2025 and management now plans about 4%, a step down it links to a more volume-driven growth profile.

    Tone shiftQ3 FY2025 → Q4 FY2025

  • Consolidated corporate practices press on price

    Corporate owners of veterinary hospitals and buying groups use their scale to negotiate lower prices, and that leverage grows as clinics consolidate.

    10-K, filed 2026-02-20

  • AI regulation and model risk touch core products

    AI drives inVue Dx and Cancer Dx results, and new U.S. rules on algorithm accountability, privacy and transparency could change how those products are validated and sold.

    10-K, filed 2026-02-20